AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01424839 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: craniospinal irradiation
Description: * Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracra-nial metastases and spinal deposits (total tumour dose 40 Gy)~* Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)~* Patients with metastastic non-germinomatous disease at diagnosis After Chemotherapy: 30 Gy (20 fractions) to cranio-spinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
Study NCT01424839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin, Etoposide, Ifosfamide
Description: • Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide
Study NCT01424839 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: ventricular irradiation
Description: * Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~* Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~* Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)
Study NCT01424839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin, etoposide, Ifosfamide (standard)
Description: Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
Study NCT01424839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin, Etoposide, Ifosfamide (high dose)
Description: Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
Study NCT01424839 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: focal irradiation
Description: • Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
Study NCT04097600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
Study NCT02107690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low temperature lidocaine injection
Description: 4 °C
Study NCT02107690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Room temperature lidocaine injection
Description: 20 °C
Study NCT02107690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Body temperature lidocaine injection
Description: 37 °C
Study NCT01909076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic decision support tools
Description: Electronic decision support tools available to both control and intervention PCPs include patient pain assessments, (Brief Pain Inventory, Pain/Enjoyment/General Function PEG), substance abuse (DAST, AUDIT) depression (PHQ9), PTSD (PTSD ChecklistCivilian), and risk of prescription drug misuse (SOAPP and COMM). The tools calculate scores with recommendation for specific action for each tool, when appropriate.
Study NCT01909076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic decision support tools
Description: Electronic decision support tools available to both control and intervention PCPs include patient pain assessments, (Brief Pain Inventory, Pain/Enjoyment/General Function PEG), substance abuse (DAST, AUDIT) depression (PHQ9), PTSD (PTSD ChecklistCivilian), and risk of prescription drug misuse (SOAPP and COMM). The tools calculate scores with recommendation for specific action for each tool, when appropriate.
Study NCT01909076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced patient education materials
Description: Patient education materials will be developed and made available to both control and intervention patients. The investigators will design the materials for patients with low literacy, using pictures and simple graphics to augment written language. The research staff will make PDFs of the materials available on the study website during and after the project.
Study NCT01909076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced patient education materials
Description: Patient education materials will be developed and made available to both control and intervention patients. The investigators will design the materials for patients with low literacy, using pictures and simple graphics to augment written language. The research staff will make PDFs of the materials available on the study website during and after the project.
Study NCT01909076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse care management
Description: The nurse/care management intervention will be modeled on BMC's successful collaborative care office-based opioid treatment (OBOT) program. One fulltime nurse care manager will work with PCPs assigned to the intervention condition. The care manager will be based centrally, in the Section of General Internal Medicine, and will divide his/her time between the 3 health centers. The main focus of the nurse care manager is to assure that patients are receiving guideline-adherent care, which involves appropriate clinical assessments, opioid treatment agreements, refill management, administering monitoring tools according to risk level (urine toxicology screen, pill counts, PMP data extraction) and timely physician visits to assess pain (minimum every 6 months).
Study NCT01909076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Patient Registry
Description: The registry will be a freestanding centralized disease management application and built using standard database technology. This system will communicate with the electronic medical record (EMR) at each community health center and with the Massachusetts State Prescription Monitoring Program (PMP) system. Data that will feed into the registry include clinical data recorded from the EMR (documentation from other clinicians and labs), data from clinical users entered into the registry via pain and opioid management forms, and the PMP. The nurse care manager will use a custom registry interface to monitor key practice activities across the entire practice at each site. The nurse care manager will use population management tools to provide aggregate measures for quality monitoring and workforce management. All quality metrics can be downloaded in aggregate form for further analysis.
Study NCT01909076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic detailing
Description: All PCPs in the intervention group will receive one 30 minute individual visit 23 months after project implementation at the PCP's practice site. The visits will be conducted with at least one of the study experts in pain medication management. Visit content will combine elements of audit and feedback (e.g. review registry of individual PCP compared with that of peers and goals) as well as traditional educational outreach. Specifically, experts will review each aspect of guideline concordant care (assessment of risk and appropriateness for opioid medication, medication dosing, monitoring for harm/adherence, and pain outcomes) to solicit barriers to implementation or lack of knowledge on the underlying evidence for each aspect of care. The experts will work with the individual PCPs to address barriers identified using motivational interviewing as needed to facilitate behavioral change in applying guideline concordant care.
Study NCT04221425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality rehabilitation system (VRRS)
Description: experimental group is equipped with a telerehabilitation system which comprises a tablet (VRRS tablet) and a set of inertial magnetic sensors. participants are invited to follow a daily rehabilitation exercise program provided via VRRS tablet
Study NCT04221425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: participants in the control group are invited to follow a daily rehabilitation exercise program and indications for the recovery as illustrated in the dimission booklets drawn up by the rehabilitation unit
Study NCT02767310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg film-coated tablets
Description: Single oral dose of 20 mg
Study NCT02767310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 20 mg film-coated tablets
Description: Single oral dose of 20 mg
Study NCT02992093 — intervention group
Intervention type: OTHER
Intervention: all the indicators
Description: BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites
Study NCT00979732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: grape seed extract
Description: grape seed extract 150 mg twice a day (BID) in beverage or capsule form
Study NCT00979732 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: grape seed extract placebo
Description: grape seed extract 150 mg twice a day (BID) in beverage or capsule form
Study NCT02563808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Decision Aid
Description: Females will receive standard decisions aid for early stage breast cancer.
Study NCT02563808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-surgical Regret Decision Aid
Description: Females will receive anticipated regret-augmented version for early breast cancer.
Study NCT03021538 — intervention group
Intervention type: DEVICE
Intervention: Extracorporeal Membrane Oxygenation
Description: ECMO is used during lung transplant procedure
Study NCT03021538 — intervention group
Intervention type: DEVICE
Intervention: Cardiopulmonary Bypass
Description: CPB is used during lung transplant procedure
Study NCT01356849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.
Study NCT01356849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
Study NCT03469297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brown Glaucoma Implant
Description: The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye. Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.
Study NCT03416647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenojejunostomy
Description: Duodenojejunostomy with or without duodenal resection
Study NCT01767298 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan/Hydrochlorothiazide
Description: Co-administration or fixed dose combination
Study NCT01767298 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan
Description: Valsartan alone
Study NCT01767298 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide alone
Study NCT04901221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extrusion arch
Description: one couple force system is applied; a custom-made extrusion wire from 0.016x0.022 stainless steel wire with helical bends placed 2-5 mm mesial to the molar tube placed in the upper and lower arches and tied distal to the lateral incisors
Study NCT00936260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alendronate
Description: several duration of treatment
Study NCT01678547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted walking
Description: The practice will included an add-on robot-assisted walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h and the BWS % will be decreased.
Study NCT01678547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: The practice will included an add-on treadmill walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial comfortable treadmill speed and the speed will be increased to a range of 1,0 to 2.5 km/h and the BWS % will be decreased.
Study NCT01678547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ground treatment
Description: The practice will included ground walking therapy s for 40 min with therapist support.
Study NCT02979015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT02979015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study NCT01776840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: 90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
Study NCT01776840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
Study NCT01776840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
Study NCT01776840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
Study NCT01776840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end
Study NCT01776840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
Study NCT04910230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinamide
Description: In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
Study NCT00205049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: daily dosing
Study NCT01327963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transoral Incisionless Fundoplication
Description: Transoral incisionless esophago-gastric fundoplication performed using the EsophyX (brand name) system with SerosaFuse (brand name) fasteners (EndoGastric Solutions, Inc., Redmond, Washington, USA) and following the standardized Transoral Incisionless Fundoplication 2.0 technique iteration (TIF2.0) protocol.
Study NCT02367638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1111
Description: Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
Study NCT02367638 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX
Description: VARIVAX is administered by subcutaneous injection
Study NCT01123681 — intervention group
Intervention type: DEVICE
Intervention: Choice of endotracheal tube
Description: Types of endotracheal tube, normal cuff without sub-glottic aspiration, normal cuff with sub-glottic aspiration, Special cuff with sub-glottic aspiration
Study NCT04680364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: partnered dance
Description: Dance classes consisted of different choreographies, which include rhythmic and simple movements typically of ballroom/standard dances (Waltz, Tango, Viennese Waltz).
Study NCT03395444 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: pulsed shortwave therapy
Description: Pulsed shortwave therapy us the RecoveryRx device. Emits a pulsed signal a the 27.12Mhz wavelength
Study NCT03395444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed shortwave therapy
Description: Pulsed shortwave therapy us the RecoveryRx device. Emits a pulsed signal a the 27.12Mhz wavelength
Study NCT02016612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Seri Surgical Scaffold
Description: An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
Study NCT03450070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Therapy Mask Cream
Description: test panel
Study NCT00359164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab
Description: Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds \[light dose of 25 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.
Study NCT00359164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab
Description: Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.
Study NCT00359164 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab
Description: Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.
Study NCT04234100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice rich in hesperidin and narirutin
Description: The product is a concentrated orange juice provided by the CITRUS Department of Florida (USA: www.FloridaCitrus.org).
Study NCT01866449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Study NCT02921737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
Study NCT04406753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy techniques in C0-1 and C2-3 with cervical exercise
Description: Manual Therapy + Exercise group will carry out 20-minute session of treatment. The techniques will be applied depending on the clinical findings in each patient and the objective will be to restore the function of C0-1 and C2-3 segments before applying cervical exercises. We will use manipulation (high velocity low amplitude) and/or mobilization (low velocity high amplitude) techniques of C0-1 and C2-3 segments with cervical exercise. Manipulations will be in the direction of traction, with the head in a neutral position. A maximum of two trials at each level on each side will perform (2-6 thrusts). Mobilization will be performed for 5 minutes using repeating cycles of 45 seconds of mobilization and 15 seconds of rest. The cervical exercise will perform by this group will follow the same methodology as the Exercise group.
Study NCT04406753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Exercise
Description: This group will perform the cervical stabilization exercise. They will be teach to perform the contraction of deep neck flexor muscle activity with the help of the Stabilizer Pressure Biofeedback Unit (Chattanooga, USA) in supine. Exercise will be always carry out without pain, because pain can be an inhibitor of muscle contraction.~The Exercise group will carry out one 20-minute session, composed of 2 sets of 10 repetitions, holding each repetition for 10 seconds, a 40-second rest between each repetition and 2 minutes between sets.
Study NCT04629404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: Firstly, intramuscularly inject 14 mg of the study drug once, continue intramuscularly inject 28 mg of the study drug once after being observed for 1 week to confirm safety, continue intramuscularly inject 42 mg of the study drug once after being observed for 1 week to confirm safety, and prepare to enter the maintenance period of 56 mg dose after being observed for 1 week to confirm safety. During the dose maintenance period, 56 mg of the test drug was intramuscularly injected once a week for a total of 4 consecutive doses.